Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group

Affiliations

• ¹ AP-HP, Pediatric Hematology and Oncology Department, Trousseau Hospital, F-75012, Paris, France. [email protected].
• ² CHU Lille, Laboratory of Hematology, F-59000, Lille, France.
• ³ INSERM, UMR-S 1172, F-59000, Lille, France.
• ⁴ AP-HP, Department of cytogenetics, Saint-Louis Hospital, F-75010, Paris, France.
• ⁵ AP-HP, Laboratory of Hematology, Trousseau hospital, F-75012, Paris, France.
• ⁶ AP-HP, Pediatric Hematology and Oncology Department, Trousseau Hospital, F-75012, Paris, France.
• ⁷ Sorbonne Université, INSERM, UMRS_938, Centre de Recherche Saint-Antoine-CRSA, F-75012, Paris, France.
• ⁸ Department of Pediatric Hematology/Oncology, University Hospital of Rennes, F-35000, Rennes, France.
• ⁹ Department of Pediatric Hematology/Oncology, University Hospital of Nantes, F-44000, Nantes, France.
• ¹⁰ Department of Pediatric Hematology/Oncology, University Hospital Charles-Nicolle, F-76000, Rouen, France.
• ¹¹ AP-HM, Department of Pediatric Hematology, La Timone University Hospital, F-13000, Marseille, France.
• ¹² Hospices civils de Lyon, Institute of Hematology and Oncology Pediatrics, F-69000, Lyon, France.
• ¹³ AP-HP, Department of Pediatric Hematology and Immunology, Robert Debre University Hospital, F-75019, Paris, France.